Rydapt 25 mg soft capsules
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 03 July 2024
File name
Rydapt_ REG PIL_PF 24-0138_clean_IPHA_July 2024.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 23 April 2024
File name
Rydapt_ REG PIL_PF 24-0083_clean_IPHA_April 2024.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 23 April 2024
File name
Rydapt_ REG PIL_PF 24-0084_clean_IPHA_April 2024.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 02 October 2023
File name
Rydapt_REG SPC_PF23-0130_June2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 31 July 2023
File name
Rydapt_ REG PIL_PF 23-0130_June2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 31 July 2023
File name
Rydapt_REG SPC_PF23-0130_July2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 17 April 2023
File name
Rydapt_REG SPC_PF23-0080_30.03.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 07 June 2022
File name
Rydapt_REG SPC_PF22-0112_IPHA_May2022.pdf
Reasons for updating
- Change to section 1 - Name of medicinal product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 07 June 2022
File name
Rydapt_REG PIL_IPHA_PF22-0112_May2022.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 15 March 2022
File name
Rydapt REG PIL PF22-0063_IPHA_Mar2022.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Updated on 11 March 2022
File name
Rydapt_REG SPC_PF22-0063_IPHA_March2022.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 19 January 2022
File name
RYDAPT_REGPIL_PF21-0219_August2021_IPHA.pdf
Reasons for updating
- Previous version of PIL reinstated
Updated on 11 January 2022
File name
Rydapt_REG SPC_PF22-0004_IPHA_Dec2021.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 10 September 2021
File name
RYDAPT REG SPC PF 21-0219 AUG2021clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 10 September 2021
File name
RYDAPT_REGPIL_PF21-0219_August2021_IPHA.pdf
Reasons for updating
- New PIL for new product
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263